You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing Novel Antibiotics Against Yersinia pestis

    SBC: NOVOBIOTIC PHARMACEUTICALS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop broad-spectrum antibiotics against Yersinia pestis and other important human pathogens. The potential use of engineered, multi-drug-resistant strains as agents of bioterrorism necessitates the development of new anti-Y. pestis therapies. This is a challenging goal, since the last novel class of broad-spectrum antib ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Modeling the Impact of Technology Transition on Ship Operational Capabilities

    SBC: BEACON INTERACTIVE SYSTEMS LLC            Topic: N05053

    During Phase I, we experimented with several transition approaches and ran into three hurdles: 1) No matter how good the method for transitioning technology, if the development process has not been well-managed, there will be no technology to transition; 2) Transition does not happen without an incredible amount of expertise and data; 3) Good technology does not matter if no one is aware of its e ...

    SBIR Phase II 2006 Department of DefenseNavy
  3. Discovery of B. pseudomallei therapeutics for Biodefense

    SBC: MICROBIOTIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Burkholderia pseudomallei is a bioterrorist threat. With the best current therapies, lethality is typically as high as 40%. The overall goal of this proposal is the development of new drugs against this organism. In Phase I, the high sequence similarity between 8. pseudomallei and its less virulent relative Pseudomonas aeruginosa was exploited to build innovati ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Automated Assistance with Metadata Generation (A2MG) Tools for PBA/IPB

    SBC: CHILIAD PUBLISHING, INC.            Topic: AF05098

    Chiliad's Phase II effort will implement and test enhancements and extensions of automated metadata generation capabilities designed in Phase I, and the tight integration of those capabilities with other software systems and applications. Some of the results of Chiliad’s SBIR funded efforts have already been deployed in operational production systems across the FBI, within new releases of the Bu ...

    SBIR Phase II 2006 Department of DefenseAir Force
  5. Vector Identification and Gene Delivery Approach in Pigs

    SBC: GWATHMEY, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Heart failure (HF) represents an enormous clinical problem demanding effective therapeutic approaches. Despite advances in traditional approaches to its treatment, including pharmacological management, myocardial revascularization, mechanical assist devices, and transplantation, heart failure remains a leading cause of death worldwide. Therefore, a novel therap ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Puerarin to Reduce Alcohol Drinking

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This application is a resubmission in response to AA-04-002 from the National Institute on Alcohol Abuse and Alcoholism to continue our STTR (Phase I and II) study on the development of NPI-031G (Puerarin), an Isoflavone-C-glycoside isolated from Puerira lobota (Kudzu), as a botanical anti-craving agent for the treatment of alcohol drinking problems. In STTR ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Saline Enhanced Radiofrequency Ablation for Liver Tumors

    SBC: E.P., LTD            Topic: N/A

    DESCRIPTION (provided by applicant): Liver cancer is a significant and increasing health concern. In the United States, there will be over 72,500 cases of colorectal cancer metastasized to the liver. Hepatocellular carcinoma (HCC) is also an increasing concern in the United States, primarily due to a rise in hepatitis C. The incidence of HCC in the United States has doubled to 17,550 cases over th ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Hybrid Molecules Designed to Enhance Antibiotic Activity

    SBC: GLSynthesis Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The worldwide resurgence of antibiotic resistant Gram-positive bacteria, especially Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium and Streptococcus pneumoniae, has stimulated discovery of novel agents that can selectively attack new bacterial targets. Through synthesis and study of compounds containing inhibitors of two validated drug targe ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid Assay for Bacterial Contamination of Platelets

    SBC: IMMUNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Addressing a major transfusion safety issue, as of March 2004, AABB statute 5.1.5.1 mandates testing of all platelet units for bacterial contamination. The only commercially available tests for this purpose in the U.S. are culture-based tests which require 48-72 hours to deliver a result. Such tests are useful only for apheresis platelet testing, but not for ra ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Hypersonic Alumina Infrared Domes

    SBC: CERANOVA CORP            Topic: N04234

    Infrared missile domes are a demanding application for materials due to severe aero-thermal heating, requiring excellent thermal shock and abrasion/erosion resistance while maintaining a high transmittance. Currently, only single-crystal alumina (sapphire) meets these demanding criteria, though at a high cost due to the processing involved in producing sapphire domes. CeraNova’s nanocrystallin ...

    SBIR Phase II 2006 Department of DefenseNavy
US Flag An Official Website of the United States Government